Related references
Note: Only part of the references are listed.The USER Study: A Chart Review of Patients Receiving a 0.2μg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema
Alexander Eaton et al.
OPHTHALMOLOGY AND THERAPY (2019)
Macular thickness amplitude changes when switching from discontinuous to continuous therapy for diabetic macular oedema
Sidney A. Schechet et al.
BMJ OPEN OPHTHALMOLOGY (2019)
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien (TM)) at 2 years
William Fusi-Rubiano et al.
BMC OPHTHALMOLOGY (2018)
Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 μg/d intravitreal implant: real-world UK experience
Ibraheem El-Ghrably et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2017)
Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom
C. Bailey et al.
EYE (2017)
A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN(R) in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsensive to Available Therapies (RESPOND)
Joao Figueira et al.
OPHTHALMIC RESEARCH (2017)
Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 μg intravitreal implant in people with diabetic macular edema
Sarah E. Holden et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Evaluation of the clinical effectiveness of fluocinolone acetonide 190 μg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes
Craig J. Currie et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 μg intravitreal implant for diabetic macular edema
Craig J. Currie et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Health-economic evaluation of fluocinolone acetonide 190 mu g implant in people with diabetic macular edema
Sarah E. Holden et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration
David Chin-Yee et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial
John A. Wells et al.
OPHTHALMOLOGY (2016)
INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY
Raj K. Maturi et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting
Ibrahim Elaraoud et al.
BMC OPHTHALMOLOGY (2016)
Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIENA®) in Patients with Diabetic Macular Edema
Ibrahim Elaraoud et al.
OPHTHALMOLOGY AND THERAPY (2016)
Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
Pascale Massin et al.
CLINICAL OPHTHALMOLOGY (2016)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
John A. Wells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results
Michael J. Elman et al.
OPHTHALMOLOGY (2015)
A novel intravitreal fluocinolone acetonide implant (Iluvien (R)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series
Vera K. Schmit-Eilenberger
CLINICAL OPHTHALMOLOGY (2015)
Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials RISE and RIDE
David M. Brown et al.
OPHTHALMOLOGY (2013)
Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2012)
Long-term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular Edema
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2011)
The RESTORE Study Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema
Paul Mitchell et al.
OPHTHALMOLOGY (2011)
CORRELATION OF VISUAL ACUITY AND MACULAR THICKNESS MEASURED BY OPTICAL COHERENCE TOMOGRAPHY IN PATIENTS WITH PERSISTENT MACULAR EDEMA
Mark S. Blumenkranz et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2010)
A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema
Michael S. Ip et al.
OPHTHALMOLOGY (2008)
Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema
David J. Browning et al.
OPHTHALMOLOGY (2007)
Share Paper
